MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences (NASDAQ:EXAS) has filed a lawsuit in federal court alleging that Geneoscopy’s ColoSense product infringes upon a key patent for its colorectal cancer screening test Cologuard.

In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ ... Stocks to Buy According to ...

In the latest quarter, 7 analysts provided ratings for Exact Sciences (NASDAQ:EXAS), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...